Fresenius Medical Care AG & Co. KGaA

Earnings Release • Aug 9, 2011

Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. Through its network of 2,838 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 225,909 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Growth Strategy

With GOAL 13…

…new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

• Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
• Acquisitions of existing clinics to ensure optimized international presence
• Horizontal expansion in the sector of Renal Drugs as well as
• A boosted activity in home therapies

Key Figures - Summary Second Quarter 2011

Net revenue	\$ 3,194 million	+ 8%
Operating income (EBIT)	\$ 510 million	+ 9%
Net income attributable to Fresenius Medical Care AG & Co. KGaA	\$ 261 million	+ 5%
Earnings per share	\$ 0.86	+ 4%
Total assets1	\$ 19,053 million
Operating cash flow2	\$ 487 million
Employees1	77,081	+ 5%
Patients1	225,909	+ 12%
Clinics1	2,838	+ 10%
Treatments2	16.56 million	+ 9%
1 as of June 30, 2011

2 in the first half of 2011

Revenue Q2 2011 per region (\$ 3,194 m)

Goals for 2011

Net revenue	> \$ 13.0 billion
Net income	\$ 1.070 - 1.090 billion
Leverage ratio (Debt/EBITDA)	< 3.0
Capital expenditures	~ 5% of revenue
Acquisitions	~ \$ 1.9 billion

Management Board Supervisory Board

• Kent Wanzek

• Dr. Ben J. Lipps (Chairman) Dr. Gerd Krick (Chairman)

• Rice Powell (Vice Chairman) Dr. Dieter Schenk (Vice Chairman)
• Michael Brosnan Dr. Walter L. Weisman
• Roberto Fusté Rolf A. Classon
• Dr. Emanuele Gatti William P. Johnston
• Dr. Rainer Runte Prof. Dr. Bernd Fahrholz

Share Profile – Key Data

Ordinary shares	Preference shares
FME	FME3
FMS	FMS/P
FMEG.DE / FMEG.F	FMEG_p.DE / FMEG_p.F
FME GY	FME3 GY
578 580	578 583
DE 0005785802	DE 0005785836
358029106	358029205

Financing Instruments and Maturity Profile

	Year issued	Amount	Coupon %	Maturity
		in million
Credit Agreement Term Loan A	2006	\$ 1,8501		March 31, 2013
Credit Agreement Term Loan B	2006	\$ 1,7501		March 31, 2013
Senior Notes 2010 - 2016	2010	€ 250	5.500%	July 15, 2016
Senior Notes 2007 - 2017	2007	\$ 500	6.875%	July 15, 2017
Senior Notes 2011 - 2021	2011	\$ 650	5.750%	February 15, 2021
Senior Notes 2011 - 2021	2011	€ 300	5.250%	February 15, 2021
Notes (Schuldscheindarlehen)	2009	€ 155		October 27, 2012
Notes (Schuldscheindarlehen)	2009	€ 45		October 27, 2014

1 at the beginning before amortisation and extension

Share Price Development last 12 months Financial Calendar

Capital Structure Contacts

		Event	Date
56,00		Report on Second Quarter 2011
54,00		Quarterly Financial Report:	August 31, 2011
52,00		Report on Third Quarter 2011
50,00		Earnings Release & Conference Call:	Nov. 2, 2011
48,00		Quarterly Financial Report:	Nov. 30, 2011
46,00		Report on Fiscal Year 2011:	February 21, 2011
44,00		Report on First Quarter 2012:	May 3, 2012
42,00		Annual General Meeting 2012:	May 10, 2012
40,00		Report on Second Quarter 2012:	August 1, 2012
01.08.10	01.11.10 01.02.11 01.05.11 01.08.11	Report on Third Quarter 2012:	October 31, 2012

Fresenius Medical Care AG & Co. KGaA Investor Relations & Corporate Communications Else-Kröner-Straße 1 61352 Bad Homburg
Oliver Maier Senior Vice President, Head of IR & CC	P:+49(0)6172-609-2525 F: +49(0)6172-609-2301
Gerrit Jost Director	P:+49(0)6172-609-5216
North America Terry L. Morris Vice President	P:+1-800-948-2538 F: +1-615-345-5605